Anti-KCNQ3/ BFNC2/ EBN2 monoclonal antibody

Anti-KCNQ3/ BFNC2/ EBN2 antibody for FACS & in-vivo assay

Target products collectionGo to KCNQ3/KCNQ3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T54132-Ab-1/ GM-Tg-hg-T54132-Ab-2Anti-Human KCNQ3 monoclonal antibodyHuman
GM-Tg-rg-T54132-Ab-1/ GM-Tg-rg-T54132-Ab-2Anti-Rat KCNQ3 monoclonal antibodyRat
GM-Tg-mg-T54132-Ab-1/ GM-Tg-mg-T54132-Ab-2Anti-Mouse KCNQ3 monoclonal antibodyMouse
GM-Tg-cynog-T54132-Ab-1/ GM-Tg-cynog-T54132-Ab-2Anti-Cynomolgus/ Rhesus macaque KCNQ3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T54132-Ab-1/ GM-Tg-felg-T54132-Ab-2Anti-Feline KCNQ3 monoclonal antibodyFeline
GM-Tg-cang-T54132-Ab-1/ GM-Tg-cang-T54132-Ab-2Anti-Canine KCNQ3 monoclonal antibodyCanine
GM-Tg-bovg-T54132-Ab-1/ GM-Tg-bovg-T54132-Ab-2Anti-Bovine KCNQ3 monoclonal antibodyBovine
GM-Tg-equg-T54132-Ab-1/ GM-Tg-equg-T54132-Ab-2Anti-Equine KCNQ3 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T54132-Ab-1/ GM-Tg-hg-T54132-Ab-2; GM-Tg-rg-T54132-Ab-1/ GM-Tg-rg-T54132-Ab-2;
GM-Tg-mg-T54132-Ab-1/ GM-Tg-mg-T54132-Ab-2; GM-Tg-cynog-T54132-Ab-1/ GM-Tg-cynog-T54132-Ab-2;
GM-Tg-felg-T54132-Ab-1/ GM-Tg-felg-T54132-Ab-2; GM-Tg-cang-T54132-Ab-1/ GM-Tg-cang-T54132-Ab-2;
GM-Tg-bovg-T54132-Ab-1/ GM-Tg-bovg-T54132-Ab-2; GM-Tg-equg-T54132-Ab-1/ GM-Tg-equg-T54132-Ab-2
Products NameAnti-KCNQ3 monoclonal antibody
Formatmab
Target NameKCNQ3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-KCNQ3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species KCNQ3/ BFNC2/ EBN2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T54132
    Target NameKCNQ3
    Gene ID3786,110862,29682,700785,475103,101093496,281884,100057886
    Gene Symbol and SynonymsBFNC2,EBN2,KCNQ3,KV7.3
    Uniprot AccessionO43525,O88944,P58126
    Uniprot Entry NameKCNQ3_HUMAN,KCNQ3_RAT,KCNQ3_BOVIN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000184156
    Target ClassificationIon Channel

    The target: KCNQ3, gene name: KCNQ3, also named as BFNC2, EBN2, KV7.3. This gene encodes a protein that functions in the regulation of neuronal excitability. The encoded protein forms an M-channel by associating with the products of the related KCNQ2 or KCNQ5 genes, which both encode integral membrane proteins. M-channel currents are inhibited by M1 muscarinic acetylcholine receptors and are activated by retigabine, a novel anti-convulsant drug. Defects in this gene are a cause of benign familial neonatal convulsions type 2 (BFNC2), also known as epilepsy, benign neonatal type 2 (EBN2). Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, May 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.